Status:
COMPLETED
Vaccination Against MSI Colorectal Cancer
Lead Sponsor:
Oryx GmbH & Co. KG
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Patients with advanced microsatellite unstable (MSI-H) colorectal cancer will be vaccinated with three so called frame shift peptides (FSPs), AIM2(-1), HT001(-1) and TAF1B(-1) combined with Montanide®...
Detailed Description
The present study is initiated to evaluate vaccination with MSI-specific FSPs in patients with MSI-H colorectal cancer. Specifically, the present study aims at the following questions: * Evaluation o...
Eligibility Criteria
Inclusion
- Phase I part inclusion criteria (inclusion criteria for phase IIa part will be defined later using a study amendment):
- Histologically confirmed, surgically resected colorectal cancer of advanced stage (UICC stage III/UICC stage IV). This comprises patients with lymph node metastases (UICC stage III), metastasis to one distant organ (UICC IV, M1a), to more than one distant organ, or patients with peritoneal carcinosis (UICC IV, M1b)
- Detection of high level microsatellite instability (MSI-H) in the resected tumor sample according to the international consensus criteria (multiplex PCR of quasi-monomorphic microsatellite markers BAT25, BAT26, CAT25), see Appendix 1.
- Prior adjuvant standard therapy (chemotherapy with 5-fluorouracil/folinic acid, oxaliplatin, irinotecan or combinations of these) OR Prior palliative standard therapy in the first, second and third line (chemotherapy with 5-fluorouracil, oxaliplatin, irinotecan or combinations of these and/or treatment with anti-EGFR antibodies cetuximab or panitumumab alone or in combination with chemotherapy) with either complete or partial remission, stable disease, or disease progression under therapy; OR Patient has refused adjuvant or palliative standard therapy (chemotherapy using 5-fluorouracil, oxaliplatin, or regimens combining these).
- Expected survival of at least six months.
- Full recovery from surgery or radiation therapy
- ECOG performance status 0, 1 or 2.
- The following laboratory results:
- Neutrophil count ≥ 1.5 x 109/L
- Lymphocyte count ≥ 0.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Serum bilirubin \< 2mg/dL
- Male or female patients ≥ 18 years old
- Last therapy discontinued at least 4 weeks prior to vaccination.
- Patient´s written informed consent for participation in the trial
Exclusion
- Prior treatment with FSPs AIM2(-1), HT001(-1) and TAF1B(-1)
- Clinically significant heart disease (NYHA Class IV).
- Other serious illnesses, eg, serious infections requiring antibiotics or bleeding disorders.
- History of immunodeficiency disease or autoimmune disease.
- Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
- HBV, HCV or HIV positivity.
- Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before study entry
- Concomitant treatment with steroids, antihistaminic drugs, or nonsteroidal anti-inflammatory drugs (unless used in low doses for prevention of an acute cardiovascular event or for pain control). Topical or inhalational steroids are permitted.
- Participation in any other clinical trial
- Pregnancy or lactation.
- Women of childbearing potential who are not using a medically acceptable means of contraception.
- Psychiatric or addictive disorders that may compromise the ability to give informed consent.
- Lack of availability of a patient for immunological and clinical follow-up assessment.
- Brain metastases (symptomatic and non-symptomatic)
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01461148
Start Date
August 1 2011
End Date
May 1 2015
Last Update
June 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Krankenhaus Nordwest
Frankfurt am Main, Germany, 60488